{"version":"1.0","type":"link","title":"Rethinking First-Line Therapy and Beyond: HER2-Positive and Hormone Receptor-Positive/HER2-Negative Metastatic Breast Cancer-Commentary Based on a Live Symposium Presented at the 2025 ESMO Congress in Berlin, Germany.","author_name":"Janni W 외","author_url":"https://prs-insight.online/author/Janni%20W","provider_name":"PRSinsight","provider_url":"https://prs-insight.online","thumbnail_url":"https://prs-insight.online/og/paper/91513","thumbnail_width":1200,"thumbnail_height":630}